ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "EP 77: ESC 22 in Review With Dr P Parwani: 5 Trials That Will Change Your Practice"
Episode Synopsis
Back by popular demand, Dr Ankur Kalra's guest is Dr Purvi Parwani, Director of Women’s Cardiovascular Disease Clinic and Assistant Professor at Loma Linda University Medical Center, US.
In this ESC 2022 edition of Parallax, Ankur asks Purvi to review her highlights of the congress. Purvi details the study design and key findings of each trial and provides her insights after attending the event in Barcelona. Ankur and Purvi discuss how each trial will inform their practice.
Trials covered in detail include:
- REVIVED: Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure (NCT01920048)
- DANCAVAS: Danish Cardiovascular Screening Trial II (NCT03946410)
- DELIVER: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (NCT03619213)
- SECURE: Secondary Prevention of Cardiovascular Disease in the Elderly Trial (NCT02596126)
- INVICTUS: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority (NCT02832544)
What are the key take-home messages of ESC 22? How can we implement these findings into daily practice? Where are the opportunities for further research?
Questions and comments can be sent to “[email protected]” and may be answered by Ankur in the next episode. Guest: @purviparwani, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.
In this ESC 2022 edition of Parallax, Ankur asks Purvi to review her highlights of the congress. Purvi details the study design and key findings of each trial and provides her insights after attending the event in Barcelona. Ankur and Purvi discuss how each trial will inform their practice.
Trials covered in detail include:
- REVIVED: Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure (NCT01920048)
- DANCAVAS: Danish Cardiovascular Screening Trial II (NCT03946410)
- DELIVER: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (NCT03619213)
- SECURE: Secondary Prevention of Cardiovascular Disease in the Elderly Trial (NCT02596126)
- INVICTUS: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority (NCT02832544)
What are the key take-home messages of ESC 22? How can we implement these findings into daily practice? Where are the opportunities for further research?
Questions and comments can be sent to “[email protected]” and may be answered by Ankur in the next episode. Guest: @purviparwani, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.
More episodes of the podcast Parallax by Ankur Kalra
EP 145: From NAFLD to MASLD: Unveiling the Cardiovascular Impact of Metabolic Liver Disease
27/10/2025
EP 142: The Psychology of Patient Care: Nudges, Gamification, and the Future of Cardiology
08/09/2025
EP 141: From EMPA-REG to Clinical Practice: Mastering SGLT2 Inhibitors in Modern Cardiology
26/08/2025
In God we trust